Erlotinib

Details

Files
Generic Name:
Erlotinib
Project Status:
Complete
Therapeutic Area:
Cancer, Lung , non-small cell
Manufacturer:
Hoffmann-La Roche Limited
Brand Name:
Tarceva
Project Line:
Reimbursement Review
Project Number:
SR0037-000
Performance Metric:
N/A — Predated performance metrics
Submission Type:
Initial
Indications:
Cancer, Lung , non-small cell
Recommendation Type:
List with clinical criteria and/or conditions
Final Recommendation:
Recommendation:
List for patients with NSCLC after failure of at least one prior chemotherapy regimen, and whose EGFR expression status is positive or unknown.